P2, P4, and P5 all exhibited significantly impaired production of type I IFN (IFNα and IFNβ) and type III IFN (IFNλ) in response to SARS-CoV-2 infection compared to healthy controls (HC), whereas responses from MIS-A patients and ICU patients with severe/critical COVID-19 were comparable (Figures 2A–C). The gene discussed is IFNA2; the disease is COVID-19.